Bing Xiang
About
In The Last Decade
Bing Xiang
39 papers receiving 458 citations
Peers
Comparison fields: 5 of 86
- Molecular Biology 199
- Oncology 96
- Cancer Research 91
- Pathology and Forensic Medicine 88
- Hematology 80
Countries citing papers authored by Bing Xiang
This map shows the geographic impact of Bing Xiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bing Xiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bing Xiang more than expected).
Fields of papers citing papers by Bing Xiang
This network shows the impact of papers produced by Bing Xiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bing Xiang. The network helps show where Bing Xiang may publish in the future.
Co-authorship network of co-authors of Bing Xiang
This figure shows the co-authorship network connecting the top 25 collaborators of Bing Xiang. A scholar is included among the top collaborators of Bing Xiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bing Xiang. Bing Xiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 1 | |
| 3 | 0 | |
| 4 | 1 | |
| 5 | 1 | |
| 6 | 4 | |
| 7 | 2 | |
| 8 | 4 | |
| 9 | 4 | |
| 10 | 25 | |
| 11 | 1 | |
| 12 | 11 | |
| 13 | 9 | |
| 14 | 0 | |
| 15 | 35 | |
| 16 | 5 | |
| 17 | 30 | |
| 18 | [Correlation analysis of EphA7 expression with clinico-pathological parameters and prognosis in tongue squamous cell carcinoma]. | 2 |
| 19 | 5 | |
| 20 | [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes]. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.